---
title: "Can-Fite BioPharma Rallies 24% on Positive Trial Data"
type: "News"
locale: "en"
url: "https://longbridge.com/en/news/284784837.md"
description: "Can-Fite BioPharma（CANF.US）现价 $3.726，当日 +24.62%，盘中涨幅显著，市值 0.04 亿。Can-Fite 专注创新药物研发，胰腺癌临床 2a 期试验数据积极，推动股价强势上行。公司近期还公布肝癌患者长生存期及合作伙伴新药入组进展，市场对其管线前景保持关注。"
datetime: "2026-04-30T13:43:18.000Z"
locales:
  - [zh-CN](https://longbridge.com/zh-CN/news/284784837.md)
  - [en](https://longbridge.com/en/news/284784837.md)
  - [zh-HK](https://longbridge.com/zh-HK/news/284784837.md)
---

# Can-Fite BioPharma Rallies 24% on Positive Trial Data

Can-Fite BioPharma (CANF.US) is trading at $3.726, up **+24.62%** intraday, with notable gains. Market cap is 4 million.

As an innovative drug developer, Can-Fite surged on encouraging pancreatic cancer Phase 2a results. The company also reported a long-term survival case in liver cancer and clinical enrollment progress from its partner, Vetbiolix. Investors remain focused on its pipeline prospects.

### Related Stocks

- [CANF.US](https://longbridge.com/en/quote/CANF.US.md)

## Related News & Research

- [Silexion Therapeutics Reports Positive Preliminary Immunotherapy Findings for SIL204 in KRAS-Driven Pancreatic Cancer | SLXN Stock News](https://longbridge.com/en/news/286425411.md)
- [Autonomix Medical Announces Abstract Acceptances at EuroPCR 2026 Showcasing Long-Term Data in Pancreatic Cancer Pain Mitigation | AMIX Stock News](https://longbridge.com/en/news/286772951.md)
- [Propanc Biopharma’s CEO Forecasts New Medical Breakthroughs in the Fight Against Pancreatic Cancer Over the Next Decade | PPCB Stock News](https://longbridge.com/en/news/287069272.md)
- [Cancer Centers Race To Access Revolution Medicines' Pancreatic Cancer Treatment: Report](https://longbridge.com/en/news/286590889.md)
- [Erasca Touts 'Eye-Popping' ERAS-0015 Lung Cancer Data, FDA Path at BofA Conference](https://longbridge.com/en/news/286652404.md)